226 related articles for article (PubMed ID: 36142566)
1. Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors.
Di Stefano M; Galati S; Ortore G; Caligiuri I; Rizzolio F; Ceni C; Bertini S; Bononi G; Granchi C; Macchia M; Poli G; Tuccinardi T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142566
[TBL] [Abstract][Full Text] [Related]
2. Identification of New GSK3β Inhibitors through a Consensus Machine Learning-Based Virtual Screening.
Galati S; Di Stefano M; Bertini S; Granchi C; Giordano A; Gado F; Macchia M; Tuccinardi T; Poli G
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139062
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study.
Jha V; Biagi M; Spinelli V; Di Stefano M; Macchia M; Minutolo F; Granchi C; Poli G; Tuccinardi T
Molecules; 2020 Dec; 26(1):. PubMed ID: 33375358
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
5. Multi-step virtual screening to develop selective DYRK1A inhibitors.
Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
[TBL] [Abstract][Full Text] [Related]
6. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.
Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS
Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765
[TBL] [Abstract][Full Text] [Related]
7. Desmodin and isopongachromene as potential inhibitors of cyclin-dependent kinase 5: phytoconstituents targeting anticancer and neurological therapy.
Atiya A; Batra S; Mohammad T; Alorfi NM; Abdulmonem WA; Alhumaydhi FA; Ashraf GM; Baeesa SS; Elasbali AM; Shahwan M
J Biomol Struct Dyn; 2023; 41(16):8042-8052. PubMed ID: 36184739
[TBL] [Abstract][Full Text] [Related]
8. Cdk5: multitasking between physiological and pathological conditions.
Lopes JP; Agostinho P
Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H
Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601
[TBL] [Abstract][Full Text] [Related]
10. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease.
Allnutt AB; Waters AK; Kesari S; Yenugonda VM
ACS Chem Neurosci; 2020 May; 11(9):1218-1230. PubMed ID: 32286796
[TBL] [Abstract][Full Text] [Related]
11. Three decades of Cdk5.
Pao PC; Tsai LH
J Biomed Sci; 2021 Nov; 28(1):79. PubMed ID: 34814918
[TBL] [Abstract][Full Text] [Related]
12. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
Chen J; Wang ZF
Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
[TBL] [Abstract][Full Text] [Related]
13. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
[TBL] [Abstract][Full Text] [Related]
14. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
15. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach.
Ambure P; Bhat J; Puzyn T; Roy K
J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
17. An in silico approach for the discovery of CDK5/p25 interaction inhibitors.
Zhang B; Corbel C; Guéritte F; Couturier C; Bach S; Tan VB
Biotechnol J; 2011 Jul; 6(7):871-81. PubMed ID: 21681969
[TBL] [Abstract][Full Text] [Related]
18. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.
Fang J; Yang R; Gao L; Yang S; Pang X; Li C; He Y; Liu AL; Du GH
Mol Divers; 2015 Feb; 19(1):149-62. PubMed ID: 25511641
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.
Wilkaniec A; Gąssowska-Dobrowolska M; Strawski M; Adamczyk A; Czapski GA
J Neuroinflammation; 2018 Jan; 15(1):1. PubMed ID: 29301548
[TBL] [Abstract][Full Text] [Related]
20. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
